Moderna Just Gave Investors Yet Another Thing to Cheer About

The Motley Fool · Matt Frankel, CFP® · 2026-11-06 14:48 UTC

Moderna's cancer vaccine has been the big story this year, but its latest quarter showed the rest of its business is improving, too.

Moderna (MRNA +1.93%) has been one of 2026's biggest stock market winners, rising nearly 720% through Thursday's close. Most of that gain can be attributed to positive late-stage trial results for its experimental cancer vaccine. But the company's third-quarter earnings report revealed something investors weren't expecting. Moderna is profitable again, for the first time in years.

A surprise profit

Moderna's revenue rose 29% year over year to $1.31 billion in the third quarter, far ahead of the roughly $890 million analysts were expecting. U.S. sales were $780 million, and international sales were $533 million. International sales of COVID vaccines were a particularly strong point.

Read the full story at The Motley Fool · All coverage of this story